This study looks at the safety of a medicine called belantamab, given through an IV (intravenous, meaning directly into a vein) to people aged 18 to 75 who have moderate to severe systemic lupus erythematosus (SLE). SLE is a disease where the body's immune system attacks its own tissues, causing inflammation and damage. The study will measure how belantamab affects the body and how its levels change over time. Participants need a body mass index (BMI) of 18 to 32, and a weight of at least 40 kg (about 88 pounds). A positive test for anti-dsDNA, a marker of lupus, is also required.
- Study Length: This is a single infusion study, meaning you will receive the medicine only once.
- Visits Needed: You may need to visit the clinic for check-ups to monitor your health and the medicine's effects.
- Risks: Those with severe lupus flares or unstable health conditions may not qualify.
Make sure to talk to your doctor to see if participating is a good choice for you.
How understandable was the trial content above?
Hard to understand
Easy to understand